CCN5/WISP-2: A micromanager of breast cancer progression

Journal of Cell Communication and Signaling

Volumn 6, Issue 2, 2012, Pages 63-71

  Banerjee, Sushanta K ^a,b   Banerjee, Snigdha ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Cell signaling; Invasion and apoptosis

Indexed keywords

CCN PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; MICRORNA 10B; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; SHORT HAIRPIN RNA; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT 1 INDUCED SIGNALING PROTEIN 2;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CELL NUCLEUS; CYTOPLASM; DISTANT METASTASIS; EPITHELIAL MESENCHYMAL TRANSITION; GAIN OF FUNCTION MUTATION; HUMAN; MITOGENESIS; NONHUMAN; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84863101632     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-012-0158-2     Document Type: Review

References (99)

1. Araki S, Eitel JA, Batuello CN, Bijangi-Vishehsaraei K, Xie XJ, Danielpour D, Pollok KE, Boothman DA, Mayo LD (2010) 69
2. TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest 120:290-302
3. Aylon Y, Oren M (2007) Living with p53, dying of p53. Cell 130:597-600 (Pubitemid 47268063)
4. Ballare C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A, Auricchio F, Beato M (2003) Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 23:1994-2008 (Pubitemid 36278811)
5. Banerjee S, Saxena N, Sengupta K, Tawfik O, Mayo MS, Banerjee SK (2003) WISP-2 Gene in Human Breast Cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation. Neoplasia 5:63-73 (Pubitemid 36151059)
6. Banerjee S, Sengupta K, Saxena NK, Dhar K, Banerjee SK (2005) Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-{alpha}- positive breast tumor cells through multiple molecular cross-talks. Mol Cancer Res 3:151-162 (Pubitemid 40524898)
7. Banerjee S, Dhar G, Haque I, Kambhampati S, Mehta S, Sengupta K, Tawfik O, Phillips TA, Banerjee SK (2008) CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res 68:7606-7612
8. Beato M, Chalepakis G, Schauer M, Slater EP (1989) DNA regulatory elements for steroid hormones. J Steroid Biochem 32:737-747
9. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavare S, Caldas C, Miska EA (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8:R214
10. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A (2006) Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25:304-309 (Pubitemid 43083692)
11. Brigstock DR (2003) The CCN family: a new stimulus package. J Endocrinol 178:169-175 (Pubitemid 37063059)
12. Bulayeva NN, Wozniak AL, Lash LL, Watson CS (2005) Mechanisms of membrane estrogen receptor-alpha-mediated rapid stimulation of Ca2+ levels and prolactin release in a pituitary cell line. Am J Physiol Endocrinol Metab 288:E388-E397 (Pubitemid 40110648)
13. Cadwell C, Zambetti GP (2001) The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 277:15-30 (Pubitemid 32972107)
14. Calin GA, Croce CM (2006a) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866 (Pubitemid 44629897)
15. Calin GA, Croce CM (2006b) MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 25:6202-6210 (Pubitemid 44527851)
16. Christofori G (2006) New signals from the invasive front. Nature 441:444-450 (Pubitemid 44050139)
17. Davies SR, Watkins G, Mansel RE, Jiang WG (2007) Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol 14:1909-1918 (Pubitemid 46870943)
18. Dhar G, Banerjee S, Dhar K, Tawfik O, Mayo MS, Vanveldhuizen PJ, Banerjee SK (2008) Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2. Cancer Res 68:4580-4587
19. Dhar G, Mehta S, Banerjee S, Gardner A, McCarty BM, Mathur SC, Campbell DR, Kambhampati S, Banerjee SK (2007a) Loss of WISP-2/CCN5 signaling in human pancreatic cancer: a potential mechanism for epithelial-mesenchymal-transition. Cancer Lett 254:63-70 (Pubitemid 47058806)
20. Dhar K, Banerjee S, Dhar G, Sengupta K, Banerjee SK (2007b) Insulin-like growth factor-1 (IGF-1) induces WISP-2/CCN5 via multiple molecular cross-talks and is essential for mitogenic switch by IGF-1 axis in estrogen receptor-positive breast tumor cells. Cancer Res 67:1520-1526 (Pubitemid 46383375)
21. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6:259-269
22. Farazi TA, Spitzer JI, Morozov P, Tuschl T (2011) miRNAs in human cancer. J Pathol 223:102-115
23. Friend S (1994) p53: a glimpse at the puppet behind the shadow play. Science 265:334-335 (Pubitemid 24259956)
24. Fritah A, Redeuilh G, Sabbah M (2006) Molecular cloning and characterization of the human WISP-2/CCN5 gene promoter reveal its upregulation by oestrogens. J Endocrinol 191:613-624 (Pubitemid 46210287)
25. Fritah A, Saucier C, De WO, Bracke M, Bieche I, Lidereau R, Gespach C, Drouot S, Redeuilh G, Sabbah M (2008) Role of WISP-2/CCN5 in the maintenance of a differentiated and noninvasive phenotype in human breast cancer cells. Mol Cell Biol 28:1114-1123 (Pubitemid 351160067)
26. Gasco M, Shami S, Crook T (2002) The p53 pathway in breast cancer. Breast Cancer Res 4:70-76 (Pubitemid 34248123)
27. Gort EH, Van HG, Verlaan I, Groot AJ, Plasterk RH, Shvarts A, Suijkerbuijk KP, Van LT, van der Wall E, Raman V, van Diest PJ, Tijsterman M, Vooijs M (2008) The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene 27:1501-1510 (Pubitemid 351347879)
28. Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127:679-695 (Pubitemid 44781029)
29. Haque I, Banerjee S, Mehta S, De A, Majumder M, Mayo MS, Kambhampati S, Campbell DR, Banerjee SK (2011) Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced signaling protein-2 (WISP-2) regulates MicroRNA-10b via hypoxia-inducible factor-1alpha-TWIST signaling networks in human breast cancer cells. J Biol Chem 286:43475-43485
30. Holbourn KP, Acharya KR, Perbal B (2008) The CCN family of proteins: structure-function relationships. Trends Biochem Sci 33:461-473
31. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53 (Pubitemid 21917115)
32. Inadera H, Dong HY, Matsushima K (2002) WISP-2 is a secreted protein and can be a marker of estrogen exposure in MCF-7 cells. Biochem Biophys Res Commun 294:602-608 (Pubitemid 34694052)
33. Inadera H, Hashimoto S, Dong HY, Suzuki T, Nagai S, Yamashita T, Toyoda N, Matsushima K (2000) WISP-2 as a novel estrogen-responsive gene in human breast cancer cells. Biochem Biophys Res Commun 275:108-114 (Pubitemid 30663638)
34. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692-696
35. Jun JI, Lau LF (2011) Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 10:945-963
36. Kalluri R (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119:1417-1419
37. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420-1428
38. Kang Y, Massague J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118:277-279 (Pubitemid 39061108)
39. Karagiannis ED, Popel AS (2007) Peptides derived from type I thrombospondin repeat-containing proteins of the CCN family inhibit proliferation and migration of endothelial cells. Int J Biochem Cell Biol
40. Kastan MB (2007) Wild-type p53: tumors can't stand it. Cell 128:837-840 (Pubitemid 46341421)
41. Kastan MB, Berkovich E (2007) p53: a two-faced cancer gene. Nat Cell Biol 9:489-491
42. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311
43. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC (2001) Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104:719-730 (Pubitemid 32241022)
44. Lake AC, Castellot JJ Jr (2003) CCN5 modulates the antiproliferative effect of heparin and regulates cell motility in vascular smooth muscle cells. Cell Commun Signal 1:5
45. Levin ER (2002) Cellular functions of plasma membrane estrogen receptors. Steroids 67:471-475 (Pubitemid 34311762)
46. Levin ER (2003) Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17:309-317 (Pubitemid 36315626)
47. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331 (Pubitemid 27131374)
48. Liang X (2011) EMT: new signals from the invasive front. Oral Oncol 47:686-687
49. Lichy JH, Dalbegue F, Zavar M, Washington C, Tsai MM, Sheng ZM, Taubenberger JK (2000) Genetic heterogeneity in ductal carcinoma of the breast. Lab Invest 80:291-301 (Pubitemid 30167789)
50. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435:834-838 (Pubitemid 40839735)
51. Ma L, Weinberg RA (2008) MicroRNAs in malignant progression. Cell Cycle 7:570-572 (Pubitemid 351498993)
52. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449:682-688 (Pubitemid 47552092)
53. Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW, Weinberg RA (2010) Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28:341-347
54. Majumder M, Banerjee S, Mehta S, De A, Dhar K, Tawfik O, Larson MA, Banerjee SK (2011) Estrogen receptor-alpha is activated in Breast ductal epithelial cells by CCN5 in CCN5-conditional Tri Transgenic mice. 102[102nd Annual American Association of Cancer Research Meeting]. 2011. Philadelphia, PA 19106, AACR. 4-4-0011. Ref Type: Conference Proceeding
55. Manolagas SC, Kousteni S (2001) Perspective: nonreproductive sites of action of reproductive hormones. Endocrinology 142:2200-2204 (Pubitemid 32473072)
56. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56 (Pubitemid 32225831)
57. Novitskiy SV, Pickup MW, Gorska AE, Owens P, Chytil A, Aakre M, Wu H, Shyr Y, Moses HL (2011) TGF-beta receptor II loss promotes mammary carcinoma progression by Th17-dependent mechanisms. Cancer Discovery 1:431-441
58. Oren M, Bartek J (2007) The sunny side of p53. Cell 128:826-828 (Pubitemid 46341426)
59. Pedram A, Razandi M, Aitkenhead M, Hughes CC, Levin ER (2002) Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J Biol Chem 277:50768-50775 (Pubitemid 36042240)
60. Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, Watanabe C, Cohen RL, Melhem MF, Finley GG, Quirke P, Goddard AD, Hillan KJ, Gurney AL, Botstein D, Levine AJ (1998) WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A 95:14717-14722 (Pubitemid 29003696)
61. Polyak K (2011) Heterogeneity in breast cancer. J Clin Invest 121:3786-3788
62. Radisky DC (2005) Epithelial-mesenchymal transition. J Cell Sci 118:4325-4326
63. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z, Bissell MJ (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436:123-127 (Pubitemid 40966197)
64. Ray G, Banerjee S, Saxena NK, Campbell DR, Van VP, Banerjee SK (2005) Stimulation of MCF-7 tumor progression in athymic nude mice by 17beta-estradiol induces WISP-2/CCN5 expression in xenografts: a novel signaling molecule in hormonal carcinogenesis. Oncol Rep 13:445-448
65. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J (1999) p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274:32631-32637 (Pubitemid 129535289)
66. Rozan LM, El-Deiry WS (2007) p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ 14:3-9 (Pubitemid 44911889)
67. Russo JW, Castellot JJ (2010) CCN5: biology and pathophysiology. J Cell Commun Signal 4:119-130
68. Sabbah M, Prunier C, Ferrand N, Megalophonos V, Lambein K, De WO, Nazaret N, Lachuer J, Dumont S, Redeuilh G (2011) CCN5, a novel transcriptional repressor of the transforming growth factor beta signaling pathway. Mol Cell Biol 31:1459-1469
69. Sato Y, Harada K, Itatsu K, Ikeda H, Kakuda Y, Shimomura S, Shan RX, Yoneda N, Sasaki M, Nakanuma Y (2010) Epithelial-mesenchymal transition induced by transforming growth factor-{beta}1/Snail activation aggravates invasive growth of cholangio-carcinoma. Am J Pathol 177:141-152
70. Saxena N, Banerjee S, Sengupta K, Zoubine MN, Banerjee SK (2001) Differential expression of WISP-1 and WISP-2 genes in normal and transformed human breast cell lines. Mol Cell Biochem 228:99-104 (Pubitemid 34121441)
71. Schutze N, Noth U, Schneidereit J, Hendrich C, Jakob F (2005) Differential expression of CCN-family members in primary human bone marrow-derived mesenchymal stem cells during osteogenic, chondrogenic and adipogenic differentiation. Cell Commun Signal 3:5
72. Sengupta K, Banerjee S, Saxena NK, Banerjee SK (2004) Thombospondin-1 disrupts estrogen-induced endothelial cell proliferation and migration and its expression is suppressed by estradiol. Mol Cancer Res 2:150-158 (Pubitemid 39030305)
73. Sengupta K, Banerjee S, Dhar K, Saxena N, Mehta S, Campbell DR, Banerjee SK (2006) WISP-2/CCN5 is involved as a novel signaling intermediate in phorbol ester-protein kinase Cα-mediated breast tumor cell proliferation. Biochemistry 45:10698-10709 (Pubitemid 44320485)
74. Shah AN, Gallick GE (2007) Src, chemoresistance and epithelial to mesenchymal transition: are they related? Anticancer Drugs 18:371-375 (Pubitemid 46712400)
75. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538-541
76. Singh G, Singh SK, Konig A, Reutlinger K, Nye MD, Adhikary T, Eilers M, Gress TM, Fernandez-Zapico ME, Ellenrieder V (2010) Sequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferation. J Biol Chem 285:27241-27250
77. Song H, Hollstein M, Xu Y (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9:573-580 (Pubitemid 46696539)
78. Song YX, Yue ZY, Wang ZN, Xu YY, Luo Y, Xu HM, Zhang X, Jiang L, Xing CZ, Zhang Y (2011) MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer 10:1
79. Steeg PS (2007) Cancer: micromanagement of metastasis. Nature 449:671-673 (Pubitemid 47552082)
80. Takahashi E, Nagano O, Ishimoto T, Yae T, Suzuki Y, Shinoda T, Nakamura S, Niwa S, Ikeda S, Koga H, Tanihara H, Saya H (2010) Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem 285:4060-4073
81. Tarin D, Thompson EW, Newgreen DF (2005) The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 65:5996-6000 (Pubitemid 40994379)
82. Teede HJ (2007) Sex hormones and the cardiovascular system: effects on arterial function in women. Clin Exp Pharmacol Physiol 34:672-676 (Pubitemid 46953117)
83. Thiery JP (2003) Cell adhesion in cancer. Comptes Rendus Physique 4:289-304 (Pubitemid 36623999)
84. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131-142 (Pubitemid 43278296)
85. Trimboli AJ, Fukino K, De BA, Wei G, Shen L, Tanner SM, Creasap N, Rosol TJ, Robinson ML, Eng C, Ostrowski MC, Leone G (2008) Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 68:937-945 (Pubitemid 351206773)
86. Ventura A, Jacks T (2009) MicroRNAs and cancer: short RNAs go a long way. Cell 136:586-591
87. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310
88. Watson CS, Norfleet AM, Pappas TC, Gametchu B (1999) Rapid actions of estrogens in GH3/B6 pituitary tumor cells via a plasma membrane version of estrogen receptor-alpha. Steroids 64:5-13 (Pubitemid 29172684)
89. Watson CS, Bulayeva NN, Wozniak AL, Finnerty CC (2005) Signaling from the membrane via membrane estrogen receptor-alpha: estrogens, xenoestrogens, and phytoestrogens. Steroids 70:364-371 (Pubitemid 40616034)
90. Watson CS, Jeng YJ, Kochukov MY (2010) Nongenomic signaling pathways of estrogen toxicity. Toxicol Sci 115:1-11
91. Wehling M (1997) Specific, nongenomic actions of steroid hormones. Annu Rev Physiol 59:365-393 (Pubitemid 27142447)
92. Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R, Kalis M, Levrero M, Strano S, Gorgoulis VG, Rotter V, Blandino G, Oren M (2007) Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 67:2396-2401 (Pubitemid 46548921)
93. Wiesman KC, Wei L, Baughman C, Russo J, Gray MR, Castellot JJ (2010) CCN5, a secreted protein, localizes to the nucleus. J Cell Commun Signal 4:91-98
94. Willis A, Jung EJ, Wakefield T, Chen X (2004) Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23:2330-2338 (Pubitemid 38496788)
95. Wyckoff MH, Chambliss KL, Mineo C, Yuhanna IS, Mendelsohn ME, Mumby SM, Shaul PW (2001) Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha(i). J Biol Chem 276:27071-27076
96. Xiang J, Wu J (2010) Feud or friend? The role of the miR-17-92 cluster in tumorigenesis. Curr Genomics 11:129-135
97. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117:927-939 (Pubitemid 38798858)
98. Yu Z, Baserga R, Chen L, Wang C, Lisanti MP, Pestell RG (2010) microRNA, cell cycle, and human breast cancer. Am J Pathol 176:1058-1064
99. Zoubine MN, Banerjee S, Saxena NK, Campbell DR, Banerjee SK (2001) WISP-2: a serum-inducible gene differentially expressed in human normal breast epithelial cells and in MCF-7 breast tumor cells. Biochem Biophys Res Commun 282:421-425 (Pubitemid 32917886)